Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Tanabe Calls For Sales of \192.0 Billion in New 3-Year Plan
May 26, 2003
- Annual Business Results
May 26, 2003
- MEDICAL DEVICE NEWS IN BRIEF
May 26, 2003
- Kissei Aims to Increase Sales, 1.3 Times by 2008: New Management Plan
May 26, 2003
- Annual Business Results
May 26, 2003
- DIAGNOSTIC NEWS IN BRIEF
May 26, 2003
- Takara Bio to Promote Anti-cancer Immunotherapy via JV
May 26, 2003
- Annual Business Results
May 26, 2003
- WORLD NEWS IN BRIEF
May 26, 2003
- Aventis Appoints "General Manufacturing/Marketing Manager" Ahead of PAL Amendment
May 26, 2003
- Korosho Calls For Healthcare Supply System Reform Centered on Patients
May 26, 2003
- BULLETIN
May 26, 2003
- Japanese Firms May Not Feel Pain If There Is Pain: Mr Kobayashi of PhRMA
May 26, 2003
- Annual Business Results
May 26, 2003
- JPMA General Assembly
May 26, 2003
- ON THE MOVE
May 26, 2003
- Dear-Doctor Letter Doesn't Decrease Panaldine ADR Reports
May 26, 2003
- Wyeth Stresses Significance of Enbrel: Mr Essner
May 26, 2003
- GE Makers to Enjoy "Golden Years" Through FY2006: President of Taiyo
May 26, 2003
- Korosho to Link 1,000 Facilities via Clinical Trial Networks
May 26, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…